Search research articles
Contact Us
Filters
Showing results (121-130 of 123) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 123 results.
Vaccine
|
March 26, 2021
Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial
J Beissbarth, N Wilson, B Arrowsmith, et al.
JCO Global Oncology
|
January 15, 2021
Prioritizing Delivery of Cancer Treatment During a COVID-19 Lockdown: The Experience of a Clinical Oncology Service in India
Indranil Mallick, Santam Chakraborty, Shweta Baral, et al.
International Journal of Pediatric Otorhinolaryngology
|
November 11, 2023
Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines
A J Leach, N Wilson, B Arrowsmith, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 123) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 123 results.
Vaccine
|
March 26, 2021
Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial
J Beissbarth, N Wilson, B Arrowsmith, et al.
JCO Global Oncology
|
January 15, 2021
Prioritizing Delivery of Cancer Treatment During a COVID-19 Lockdown: The Experience of a Clinical Oncology Service in India
Indranil Mallick, Santam Chakraborty, Shweta Baral, et al.
International Journal of Pediatric Otorhinolaryngology
|
November 11, 2023
Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines
A J Leach, N Wilson, B Arrowsmith, et al.
Page
of 13